MRK—Synopsis of (anti-LAG-3) favezelimab data from ASCO abstract: https://www.biopharmadive.com/news/asco-merck-favezelimab-lag3-hodgkin-trial/624457/ Favezelimab might eventually compete with BMY’s Opdualag (#msg-168259768), but it has a long way to go. Please see #msg-168259803 and https://twitter.com/DewDiligence/status/1395141087413538822 for related info.